AstraZeneca, Daiichi Sankyo Enhertu gets EU approval for earlier use in breast cancer subtype
olrat


The European Commission (EC) approved AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) (OTCPK:DSNKY) Enhertu to treat certain patients with breast cancer.
Enhertu (trastuzumab deruxtecan) can now be used as a monotherapy to treat adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

The EC approval follows positive opinion by a panel of the European Medicines Agency.
The approval was backed by data from a phase 3 trial called DESTINY-Breast03.
AstraZeneca (AZN) added that due to the EU approval, it is due to pay $75M to Daiichi Sankyo as a milestone payment in 2nd-line HER2-positive metastatic breast cancer as per their collaboration agreement.